The advancement of technology has created more opportunities for Next-Generation Sequencing (NGS). With greater public interest in Precision Medicine, it seems hopeful that NGS can potentially change the paradigm in oncology diagnostics and treatment decision-making.
To realise the potential of NGS, different stakeholders should work together to establish more effective and market-appropriate national policy strategies. These strategies should focus on reinforcing the value of quality NGS as well as ensuring the need for quality assurance and standardisation.
In this paper, we will share our recommendations on ensuring standardisation and quality NGS across the region.